Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension
(D1AMOND Trial)
Recruiting at64 trial locations
Age: < 65
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Emalex Biosciences Inc.
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?
This trial tested the safety of ecopipam tablets for children and adolescents with Tourette Syndrome. The medication aims to help manage their symptoms by affecting brain chemicals. Participants took the medication for an extended period with frequent check-ups. Ecopipam has shown promise in previous studies.
Research Team
Eligibility Criteria
Inclusion Criteria
Subjects must have completed the EBS-101-CL-001 study through the Day 14 Follow Up Visit within the last 30 days (or longer with permission of the medical monitor) without a major reportable protocol deviation and must be someone the Investigator feels would benefit from continued participation.
Treatment Details
Interventions
- Ecopipam (Dopamine D1 Receptor Antagonist)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: EcopipamExperimental Treatment1 Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Emalex Biosciences Inc.
Lead Sponsor
Trials
16
Recruited
1,000+